melanoma cells and additional human PDX isolates were treated with vehicle control, pazopanib (1 µM), AR42 (600 nM) or the drugs in combination for 24 h. Floating cells were cyto-spun onto the 96 well plate and cell viability determined using a live/dead viability stain (n = 3 +/-SEM). *p < 0.05 greater than either pazopanib alone or AR42 alone values. (B-F) Tumor cells were treated with vehicle control, pazopanib (1 µM), AR42 (600 nM) or the drugs in combination for 24 h. Floating cells were cyto-spun onto the 96 well plate and cell viability determined using a live/dead viability stain.
Supplementary Figure 2: Pazopanib and sodium valproate interact to kill melanoma and ovarian cancer cells. (A)
Melanoma cells and (B) ovarian cancer cells were treated with vehicle control, pazopanib (1 µM), sodium valproate (250 µM) or the drugs in combination for 24 h. Floating cells were cyto-spun onto the 96 well plate and cell viability determined using a live/dead viability stain (n = 3 +/-SEM).
# p < 0.05 greater than either pazopanib alone or AR42 alone values.
Supplementary Figure 3:
Pazopanib and AR42 interact to modulate the expression and phosphorylation of multiple intracellular proteins. cells were treated with vehicle control, pazopanib (1.0 µM), AR42 (600 nM) or the drugs in combination for 6 h. Cells were then fixed in place with permeabilization. Immuno-fluorescence was performed at 10X magnification in a Hermes wide field microscope to determine the gross changes in the phosphorylation and total expression of the indicated proteins (representative images are shown, n = 3 +/-SEM). # p < 0.05 greater than either pazopanib alone or AR42 alone values. *p < 0.05 less than either pazopanib alone or AR42 alone values.
Supplementary Figure 4:
Pazopanib and AR42 interact to kill melanoma cells through death receptor signaling; autophagy; and ER stress signaling. and MEL28-R cells were either: transfected with an empty vector plasmid (CMV) or with plasmids to express dominant negative caspase 9, BCL-XL or c-FLIP-s; or with a scrambled siRNA (siSCR) or with siRNA molecules to knock down the indicated proteins. Twenty-four h after transfection cells were treated with vehicle control, pazopanib (1 µM), AR42 (600 nM) or the drugs in combination for 24 h. Floating cells were cyto-spun onto the 96 well plate and cell viability determined using a live/dead viability stain (n = 3 +/-SEM).
¶ p < 0.05 greater than corresponding value in siSCR transfected cells; *p < 0.05 less than corresponding value in siSCR cells # p < 0.05 less than corresponding value in siCD95 cells.
Supplementary Figure 5: AR42 facilitates pazopanib binding to the NH2-termini of chaperone proteins. TPF-12-293
cells were treated with vehicle control, pazopanib (1 µM), AR42 (600 nM) or the drugs in combination for 6 h. Cells were fixed in place and permeabilized, and immuno-fluorescence performed to detect the expression of the indicated proteins; multiple antibodies were used to detect the expression of each chaperone with epitopes in the NH2-terminus, the central portion of the protein and the COOH-terminus (n = 3 +/-SEM) ¶ p < 0.05 less than value in pazopanib alone.
Supplementary Figure 6: HDAC6 regulates the induction of autophagosomes by [pazopanib + AR42]
. melanoma cells were transfected with a plasmid to express LC3-GFP and in parallel co-transfected with either an empty vector plasmid; a plasmid to express wild type HDAC6; or a plasmid to express dominant negative HDAC6; or transfected with a scrambled siRNA or an siRNA to knock down HDAC6 expression. Twenty-four h after transfection cells were treated with vehicle control or with [pazopanib (1 µM) + AR42 (600 nM)] for 6h. The numbers of punctate LC3-GFP staining vesicles were counted in at least 40 cells per condition and the mean number of vesicles per cell plotted (n = 3 +/-SEM) *p < 0.05 greater than corresponding value in CMV/SCR cells; # p < 0.05 less than corresponding value in CMV/SCR cells. 
